EP2680917A1 - Systèmes d'administration de médicament actionnés par pression implantables et procédés de fabrication et d'utilisation - Google Patents

Systèmes d'administration de médicament actionnés par pression implantables et procédés de fabrication et d'utilisation

Info

Publication number
EP2680917A1
EP2680917A1 EP11707985.5A EP11707985A EP2680917A1 EP 2680917 A1 EP2680917 A1 EP 2680917A1 EP 11707985 A EP11707985 A EP 11707985A EP 2680917 A1 EP2680917 A1 EP 2680917A1
Authority
EP
European Patent Office
Prior art keywords
rupture
cavity
frangible layer
pressure
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11707985.5A
Other languages
German (de)
English (en)
Inventor
Chao-Wei Hwang
Hala J. TOMEY
Jon R. RESAR
Robert C. MATTESON, III
George L. COLES, Jr.
Jason J. BENKOSKI
Morgana M. TREXLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of EP2680917A1 publication Critical patent/EP2680917A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0071—Additional features; Implant or prostheses properties not otherwise provided for breakable or frangible
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0244—Micromachined materials, e.g. made from silicon wafers, microelectromechanical systems [MEMS] or comprising nanotechnology

Definitions

  • Mechanically actuated substance delivery methods and systems including implantable, pressure-actuated drug delivery methods and systems.
  • Coronary stents are commonly used to treat heart attacks. Stents, however, have been known to abruptly clot. Conventional stent clot treatment includes emergency angioplasty, which is expensive, difficult to coordinate, and accompanied by relatively high mortality rates.
  • Stents have been coated with drugs ("drug-eluting stents") to reduce the formation of scar tissue.
  • drug-eluting stents have been shown to increase the likelihood of abrupt in-stent clot formation.
  • Stents have been textured and coated with antibodies and proteins to attract native cell coverings in attempts to promote vessel healing and reduce clot formation, without much success and, in some cases, with increased clotting. Furthermore, such passive systems are not able to sense nor adapt to new clots that may occur.
  • Conventional intracoronary drag-delivery systems are passive. Drugs are released with pre-determined kinetics, and these systems cannot sense nor respond to new, abrupt environmental changes such as clotting. Active drug delivery systems deliver drugs in response to an external stimulus, but conventional systems require a bulky or externalized power source, a separate sensor and are unsuitable for intracoronary application.
  • Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use.
  • a pressure-rupturable membrane or diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within or after a desired rupture time.
  • the diaphragm may be tuned by selection of material, controlling a thickness, patterning a surface, patterning an underlying substrate support, and/or changing the material composition of the diaphragm.
  • the cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature diaphragm rupture in an ambient environment and to dissipate within an implant environment.
  • the cavity may be pressurized above an implant environment pressure, such as a blood vessel pressure.
  • diaphragm integrity is maintained by counteracting pressure of the implant envirnment.
  • the counteracting pressure of the implant environment falls, such as loss of blood pressure due to an occlusive blood clot, and the pressure difference across the diaphragm falls, the diaphragm ruptures and the drug and/or other substance is released or delivered into the implant environment.
  • the drug and/or other substance may include, without limitation, a thrombolytic, plasminogen, plasmin, heparin, and/or other anti-thrombotic agent, antiplatelet agent, anti-inflammatory agent, immunomodulator, and/or other enzyme or protein, DNA, RNA, mRNA and/or other genetic material, virus particles, cells, small molecule, anti-lipid agent, and/or medication.
  • Methods and systems disclosed herein may be implemented alone and/or in combination with one or more other implant platforms, such as a stent, including a coronary and a non-coronary or peripheral stent.
  • implant platforms such as a stent, including a coronary and a non-coronary or peripheral stent.
  • FIG. 1 is a block diagram of a pressure-actuated drug delivery system, including a substrate and a pressure-rupturable diaphragm to releasably retain a drug within a cavity of the substrate.
  • FIG. 2 is a flowchart of a method of fabricating a pressure-actuated drug delivery system.
  • FIG. 3 is a graphic illustration of a fabrication stage of the drug delivery system of FIG. 1.
  • FIG. 4 is a graphic illustration of another fabrication stage of the drug delivery system of FIG. 1.
  • FIG. 5 is a graphic illustration of another fabrication stage of the drug delivery system of FIG. 1.
  • FIG. 6 is a graphic illustration of another fabrication stage of the drug delivery system of FIG. 1.
  • FIG. 7 is a flowchart of a method of fabricating a pressure-rupturable diaphragm.
  • FIG. 8 is a graphic illustration of a progression of fabrication stages of a pressure-rupturable diaphragm.
  • FIG. 9 is a flowchart of a method of fabricating a drug cavity.
  • FIG. 10 is a graphic illustration of a progression of fabrication stages of a drug cavity.
  • FIG. 11 is a flowchart of a method of disposing a diaphragm protector over a diaphragm, disposing a drug within a cavity, and sealing the cavity.
  • FIG. 12 is a graphic illustration of a progression of stages of disposing a diaphragm protector over a diaphragm, disposing a drug within a cavity, and sealing the cavity.
  • FIG. 13 is a block diagram of another drug delivery system, including example dimensions.
  • FIG. 14 is a flowchart of a method of using an implantable pressure- actuated substance delivery system.
  • FIG. 15 is a flowchart of a method of using an implantable pressure- actuated drug delivery system within a vascular implant environment to treat a potential blood clot.
  • FIG. 16 is a flowchart of a method of using an implantable pressure- actuated substance delivery system that includes one or more of a hydrogel and a sensory agent.
  • FIG. 1 is a block diagram of a pressure-actuated drug delivery system 100, including a substrate 102 and a pressure-rupturable diaphragm 104 to releasably retain a drug 106 within a cavity 106 of substrate 102.
  • Diaphragm 104 may be configured to rupture upon a pre-determined pressure difference across first and second surfaces or sides 110 and 112, referred to herein as a rupture threshold.
  • a pressure on surface 110 may be a predetermined pressure, which may be set during fabrication and/or prior to or at the time of implantation.
  • a pressure on surface 112 may correspond to an implant environment pressure, such as a vascular blood pressure.
  • the rupture threshold may be a function of a material and physical characteristics of diaphragm 104. Physical characteristics may include thickness, and/or other physical features of diaphragm 104. For example, surface 112 may have ridges, walls, posts, grooves, depressions, and/or other physical features formed therein, which may served to anchor and/or stiffen diaphragm 104. Physical characteristics of diaphragm 104 may be configured to control the rupture threhsold, and may be designed with assistance of a finite element analysis (FEA).
  • FFA finite element analysis
  • the rupture threshold may further be a function of substrate features within cavity 108, such as described in examples below.
  • Material and/or physical characteristics of diaphragm 104 and/or substrate features within cavity 108 may also be configured to control a rupture site, rupture pattern, and/or rupture time, such as described in examples below.
  • Diaphragm 104 may include one or more layers or films of one or more materials to form a frangible layer.
  • Substrate 102 and diaphragm 104 may be fabricated from one or more materials that remain relatively stable within an implant environment for at least a pre-determined time, referred to herein as an operating life of system 102, and may include a material that will remain relatively stable within the implant environment beyond the operating life. Stability may be measured in terms of dissolution, bio-degradation, dissipation, and/or corrosion within the implant environment.
  • clopidogrel a blood thinner
  • clopidogrel a blood thinner
  • Several pathology studies suggest that, at least with respect to animals, a stented blood vessel may need up to two or more 2 years to heal.
  • substrate 102 and diaphragm 104 may thus be fabricated from one or more materials that will remain relatively stable within a blood vessel for up to one year, up to two years, or longer. Methods and systems disclosed herein are not, however, limited to a pre-determined period of time or an operating life.
  • Substrate 102 and diaphragm 104 may be fabricated, for example, from one or more metals and/or non-metal materials.
  • a metal may include, without limitation, one or more of chromium, titanium, nickel, cobalt, gold, tungsten, and/or combinations and/or alloys thereof.
  • a non-metal material may include, without limitation, silcon dioxide and/or other a silicon compound, and/or a polymer that remains stable over the operating life, which may include a polylactic or polyglycolic acid.
  • Substrate 102 may include a silicon substrate, and diaphragm 104, or portions thereof, may be spin-coated and/or deposited by electron-beam evaporation onto a surface of substrate 102, such as described in one or more examples below.
  • Physical features may be imparted to diaphragm 104, such as with photo-lithographic etching, such as described in one or more examples below.
  • Cavity 108 may be pressurized and/or evacuated based on an implant environment, and diaphragm 104 may be configured with a rupture threshold based on a potential adverse pressure change within the implant environment. Cavity 108 may be pressurized to a pressure substantially equal to a sum of a desired rupture pressure and a rupture threshold of diaphragm 104. Conversely, the rupture pressure may be defined as a difference between the cavity pressure and the rupture threshold.
  • system 100 is implanted within a blood vessel, for example, normal physiological blood pressure maintains sufficient pressure against diaphragm surface 112 to prevent rupture.
  • counteracting physiological blood pressure at diaphragm surface 112 may fall below the pre-determined rupture pressure, which may cause diaphragm 104 to rupture and relase drug 106 and/or other substance into the blood vessel to contact the clot.
  • Drug 106 may include one or more drugs to mechanically disrupt and/or enzymatically degrade the clot, which may re-establish blood flow.
  • Example pressure values are provided below with respect to a blood vessel implant environment and an example rupture threshold. Methods and systems disclosed herein are not, however, limited to any of the pressure values or the implant environment of the examples below. In the examples below, presure values are provided below in millimeters of mercury (mmHg), relative to one (1) atmosphere.
  • mmHg millimeters of mercury
  • a normal systolic blood pressure may be within a range of approximately 100-140 mmHg.
  • a normal diastolic blood pressure may be within a range of approximately 70-90 mmHg.
  • a lowered blood pressure indicative of a distal clot may be within a range of approximately 5-20 mmHg.
  • Cavity 108 may be pressurized based on a desired rupture pressure (e.g., a lowered blood pressure), and a diaphragm rupture threshold.
  • a desired rupture pressure e.g., a lowered blood pressure
  • a diaphragm rupture threshold e.g., a lowered blood pressure
  • the desired rupture pressure may be patient specific and/or implant location specific, and may be determined in consultation with a medical professional.
  • a desired rupture pressure may be, for example, approximately 40 mmHg.
  • a rupture threshold of an example chromium based diaphragm may be approximately 300 mmHg.
  • Cavity 108 may thus be pressurized to approximately at 340 mmHg to cause diaphragm 104 to rupture when the blood pressure falls below 40 mmHg.
  • cavity 108 may be pressurized to less than or greater than 340 mmHg, including less than or equal to 300 mmHg, greater or equal to 1000 mmHg, and may be within a range of approximately 300 mmHg to 1000 mmHg, within a range of approximately 200 mmHg to 1200 mmHg, or may be evacuated, depending upon the desired rupture pressure and the rupture threshold.
  • diaphragm 104 may be fabricated and/or subsequently configured to provide a rupture threshold less than or greater than 300 mmHg, including less than or equal to 200 mmHg, less than or equal to 1200 mmHg, and may be within a range of approximately 200 mmHg to 1200 mmHg.
  • a rupture pressure may be greater or less than 40 mmHg, including less than or equal to 20 mmHg, less than or equal to 50 mmHg, and may be within a range of approximately 20 mmHg to 50 mmHg.
  • Diaphragm 104 may be fabricated and/or subsequently configured to rupture substantially immediately upon exposure to a rupture pressure.
  • diaphragm 104 may be fabricated and/or subsequently configured to maintain integrity when exposed to the rupture pressure for less than a pre- determined period of time, and to rupture after exposure to the rupture pressure for at least a pre-determined period of time. Such a pre-determined period of time is referred to herein as a rupture time.
  • Delayed rupture may be useful, for example, to prevent rupture due to a spurious condition, such as a spurious drop in blood flow that may not be indicative of a blood clot.
  • Diaphragm 104 may be fabricated and/or subsequently configured to rupture upon exposure to a rupture pressure of, for example, within 5 seconds, after at least 5 seconds, within 15 second, after at least 15, within 60 seconds, or after at least 60 seconds or more.
  • System 100 may include a dissolvable and/or bio-degradable diaphragm protector 114 disposed over second surface 112 of diaphragm 104, which may be configured to prevent premature rupture of diaphragm 104.
  • Diaphragm protector 114 may be useful to protect diaphragm 104 from rupture prior to implantation, such as where an ambient or pre-implant environment pressure is below the rupture pressure.
  • Diaphragm protector 114 may include one or more water-soluble and/or bio-degradable materials, such that diaphragm protector 114 substantially dissolves, bio-degrades, or otherwise dissipates within an implant environment.
  • Diaphragm protector 114 may include, for example, a water-soluble polymer, and may include one or more relatively long chain polyethylene glycols of varying molecular weights.
  • diaphragm protector 114 may include a biodegradable polymer, such as a polylactic and/or polylactic-co- glycolic acid.
  • diaphragm protector 114 may be spun onto diaphragm surface 112 to a thickness sufficient to protect diaphragm 104 from mechanical and pressure-related damage during fabrication, storage, shipping, and/or implantation.
  • Diaphragm 104 may have a thickness of, for example, greater than 10 micrometers (um).
  • Drug 106 within cavity 108 may include, without limitation, a thrombolytic, plasminogen, plasmin, heparin, and/or other anti -thrombotic agent, antiplatelet agent, anti-inflammatory agent, immunomodulator, and/or other enzyme or protein, DNA, RNA, mRNA and/or other genetic material, virus particles, cells, small molecule, anti-lipid agent, and/or medication.
  • Drug 106 and/or cavity 108 may include one or more compounds or agents 116 applied to a surface of cavity 108 and/or within an interior portion of cavity 108.
  • Agent 116 may include a swelling agent to expand upon contact with a fluid, which may help to expel drug 106 from cavity 108 into the implant environment.
  • the swelling agent may expand to occupy all or substantially all of cavity 108.
  • the swelling agent may include a hydrogel, such as a drug-eluting hydrogel, which may include one or more of an anti-coagulant, such as heparin, a thrombolytic, and/or other drug.
  • Agent 116 and/or drug 106 may include an indicator to alert the patient when membrane 104 releases drug 106.
  • the indicator may include, for example, allyl methyl sulfide, a compound that provides a garlic sensation.
  • Drug delivery system 100 may be implemented as a stand-alone implantable platform, and/or may be affixed to, embedded with, and/or integrated within another implantable platform. Drug delivery system 100 may, for example, be embedded within wells of a metal ring and/or a stent to be implanted within a vascular passage.
  • Drug delivery system 100 may be implemented, for example, as part of a coronary and/or non- coronary stent.
  • Non-coronary stents may be implemented to treat non-coronary vessels, such as carotid, renal, subclavian, aorta, femoral, popliteal, iliac and other arteries.
  • System 100 may be implemented, for example, to treat peripheral artery disease (PAD), which may affect femoral, popliteal, iliac and other arteries.
  • PAD peripheral artery disease
  • Non-coronary stents are also referred to herein as peripheral stents and PAD stents.
  • Peripheral stents may need more flexibility than coronary stents because lesions may be longer and may be located between muscle and bone in the legs, which may place greater stress and torque on a stent.
  • a peripheral stent may be implemented as a self-expanding stent, and may be manufactured from a relatively flexible nickel -titanium alloy developed by the U.S. Naval Ordinance Lab, commercially known as Nitinol, an acronym for Nickel Titanium Naval Ordinance Laboratory.
  • drug delivery system 100 may be incorporated within a stent, the stent may be implanted within an vessel, such as a coronary artery, using conventional percutaneous techniques. Once implanted, drug delivery system 100 may operate without external sensory or control intervention.
  • Drug delivery system 100 may be implemented to treat heart attacks caused by occlusive coronary clots, and may be retroactively placed in a patient who has already received a stent. Other example implementations are provided below.
  • Drugs and/or endocrine conditions may lead to a critical rise in blood pressure.
  • Drug delivery system 100 may be implemented to release anti- hypertensive drugs when blood pressure exceeds a pre-determined threshold.
  • Fluid overload in a patient suffering from heart failure may experience an increase in central venous pressure (CVP), which may be treated with diuretics.
  • CVP central venous pressure
  • Drug delivery system 100 may be implemented to release diuretics when the CVP exceeds a pre-determined threshold.
  • Drug delivery system 100 may be incorporated within the arteriovenous conduit to release thrombolytics to clear the clot from the conduit.
  • Anaphylaxis is a sudden allergic reaction that can cause a fatal drop in blood pressure.
  • Drug delivery system 100 may be implemented to relese epinephrine, corticosteroids and/or anti-histamines to prevent and/or ameliorate anaphylactic shock.
  • Drug delivery system 100 may be implemented to repond to intracranial pressure by releasing steroids and/or diuretics to provide additional time for neurosurgical decompression.
  • System 100 may be implemented to release vasopressants when blood pressure falls as a result of trauma, which may temporarily sustain blood pressure until medical assistance is provided.
  • System 100 may be implemented to repair a non-biological system, such as to release a liquid sealant to seal a puncture in reponse to a pressure change.
  • System 100 may include a layer or membrane laced with a high-resistivity heating wire, such as nickel-chromium alloy wire.
  • the coil may be inductively heated with a magnetic resonance coil to melt the membrane and expose diaphragm 104 and/or diaphragm protector 114.
  • a wire-laced membrane may be implemented as diaphragm 104.
  • system 100 may be fabricated on a shared substrate, which may be cut into portions of one or more instances of system 100.
  • Subsets of instances of system 100 may be configured with different rupture thresholds, which may permit delivery of drugs in response to different environmental pressures.
  • Subsets of instances of system 100 may also be provisioned with different drugs and/or combinations of drugs, which may permit delivery of different drugs in response to different environmental pressures.
  • Subsets of instances of system 100 may include membranes having disparate melting points, such as different formulations of ethylene vinyl acetate copolymer, and the membranes may be laced with the high-resistivity heating wire described above to permit selective activation of the the instances of system 100.
  • the shared substrate may be cut to provide an implantable substrate that includes multiple instances of system 100, which may include multiple rupture thresholds, multiple drugs and/or combinations of drugs, and/or membranes having disparate melting temperatures.
  • An ultrasound transducer may be implanted physically proximate to system 100 to emit signals at a resonnant wavelength of cavity 108 to rupture diaphragm 104 with relatively minimal energy.
  • the acousitic signals may have a wavelength substantially equal to integer multiple of 4L, where L is depth of cavity 106.
  • the ultrasound transducer may be used as actuate drug delivery system 100 independently of an implant environment pressure, and/or may be used as a back-up actuator.
  • the ultrasound transducer may be coupled to an ECG sensor to actuate drug delivery system 100 when the ECG sensor detects ST segment elevations.
  • FIG. 2 is a flowchart of a method 200 of fabricating a pressure-actuated drug delivery system. For illustrative purposes, method 200 is described below with reference to FIGS. 1 and 3 through 6.
  • FIGS. 3-6 are graphic illustrations of stages of fabrication of drug delivery system 100. Method 200 is not however, limited to any of the examples of FIGS. 1 and 3 through 6.
  • diaphragm 104 is disposed over a surface of substrate 102, as illustrated FIG. 3, such as by spin-coating and/or electron-beam deposition or evaporation.
  • diaphragm protector 114 is disposed over diaphragm 104, as illustrated FIG. 4.
  • diaphragm protector 114 may be disposed over diaphragm 104 subsequent to formation of cavity 108 at 206.
  • cavity 108 is formed within substrate 102, to expose at least a portion of diaphragm surface 110 to cavity 108, as illustrated FIG. 5.
  • drug 106 is disposed within cavity 108, and cavity 108 pressurized and hermetically sealed.
  • cavity 108 is sealed with a material 602, which may be substantially similar to a material of substrate 102.
  • Drug 106 may be disposed within cavity 108 by direct microinjection using one or more conventional micro-injection techniques. Alternatively, or additionally, drug 106 may drug may be disposed within cavity 108 with a nebulization process.
  • the nebulization process may include masking exposed portions 118 of substrate 102 with a protective shadow mask. A drug solution may be supersaturated or concentrated at a solubility limit, and aerosolized into relatively fine droplets using a jet nebulizer. As the droplets accumulate on the shadow mask and within cavity 108, solvent within the droplets evaporates, leaving behind a film of drug crystals. The nebulizing process may continue until a desired drug mass is provided within cavity 108. The shadow mask may then be removed.
  • One or more agents 116 may be applied to an inner surface of material 602 prior to sealing cavity 108.
  • Cavity 108 may be pressurized prior to sealing cavity 108.
  • pressurization of cavity 108 may be achived by hermetically sealing cavity 108 in a pressurized atmosphere.
  • Cavity 108 may be pressurized subsequent to sealing of cavity 108.
  • pressurization of cavity 108 can be achieved by hermetically sealing cavity 108 under relatively low-temperature conditions. Pressurization then ensues with expansion of gas within cavity 108 when warmed to ambient and/or body temperature.
  • a specific pressure and/or temperature at which cavity 108 is hermetically sealed may be selected based on a desired rupture pressure and rupture threshold.
  • Air transport through metal is relatively negligible and may be further reduced and/or minimized by sealing cavity 108 within a high molecular weight inert gas atmosphere, such as argon or xenon.
  • Cavity 108 may be sealed using one or more of a variety of types of sealants, which may include a conventional silicon adhesive, such as an epoxy and/or a crystal-bonding sealant, and/or a low-temperature ultrasound-assisted bonding technique.
  • sealants may include a conventional silicon adhesive, such as an epoxy and/or a crystal-bonding sealant, and/or a low-temperature ultrasound-assisted bonding technique.
  • Method 200 may be implemented to form a plurality of cavities within a shared substrate, and may include cutting or dicing the substrate into multiple substrates, each including one or more drug-containing cavities, such as described above. Where method 200 is implemented to form a plurality of cavities, different drugs and/or combinations of drugs may be disposed within different cavities at 208, such as with one or more masking procedures. Similarly, diaphragms having different rupture thresholds may be disposed over different cavities. The substrate may be cut to provide a substrate having multiple cavities, which may include different drugs or combinations of drugs, and/or different rupture thresholds.
  • FIG. 7 is a flowchart of a method 700 of fabricating a pressure-rupturable diaphragm. Method 700 is described below with reference to example materials for illustrative purposes. Method 700 is not, however, limited to the example materials described below.
  • Method 700 is further described with reference to FIG. 8, which is a graphic illustration of a progression of fabrication stages of a pressure-rupturable diaphragm. Method 700 is not, however, limited to the example of FIG. 8.
  • a polished silicon wafer 802 is thermally oxidized to create a silicon dioxide layer 804.
  • Titanium layer 806 is deposited over silicon dioxide layer 804. Titanium layer 806 may be deposited by electron-beam evaporation under high vacuum, and may have a thickness within a range of approximately 5- 30 nanometers (nm).
  • Chromium layer 808 is deposited onto titanium layer 806.
  • Chromium layer 808 may be deposited by electron-beam evaporation under high vacuum, and may have a thickness within a range of approximately 50-120 nm.
  • a negative photoresist 810 is deposited onto chromium layer 808.
  • Negative photoresist 810 may be spin deposited, and may have a thickness in excess of 1000 nm.
  • portions of negative photoresist 810 are masked (see mask 812 in FIG. 8).
  • one or more features and/or patterns of features are photolithographically etched in negative photoresist 810, based on the masking at 710.
  • the features may include walls 814 extending from chromium layer 808 defining trenches 815 therebetween.
  • a second chromium layer 816 is deposited over chromium layer 808.
  • Second chromium layer 816 may be deposited by electron-beam evaporation, and may have a thickness within a range of approximately of 30-50 nm. Chromium layers 808 and 816, together, may have a minimum thickness of approximately 80 nm.
  • photoresist 810 is removed from chromium layers 808 and 816, leaving a rupturable diaphragm 818, including titanium layer 806 and chromium layers 808 and 816, and having a pattern of grooves 820 formed therein.
  • FIG. 9 is a flowchart of a method 900 of fabricating a drug cavity.
  • Method 900 is described below with reference to example materials for illustrative purposes. Method 900 is not, however, limited to the example materials described below.
  • Method 900 is further described with reference to FIGS. 8 and 10.
  • FIG. 10 is a graphic illustration of a progression of fabrication stages of a drug cavity. Method 900 is not, however, limited to the examples of FIGS. 8 and 10.
  • a positive photoresist 1002 is spun onto a surface of substrate 802.
  • positive photoresist 1002 is masked with a mask 1004.
  • positive photoresist 1002 is eteched in accordance with mask 1004 to expose a portion 1006 of the surface of substrate 802, and mask 1004 is removed.
  • a cavity 1008 is etched into substrate 802 through exposed portion 1006 of substrate 802.
  • silicon dioxide layer 804 may structurally support diaphragm 818.
  • exposed portions of silicon dioxide layer 804 are removed, such as with a wet-etching process, which may utilize hydrofluoric acid to remove release diaphragm 804 from silicon dioxide layer 804.
  • positive photoresist 1002 may be eteched to create one or more physical features or shapes such as, for example, lines, circles, ellipses, and/or one or more polygons.
  • substrate 802 may be etched in accordance with the one or more physical features or shapes of positive photoresist 1002 until silicon dioxide layer 804 is reached, such as with an STS- DRIE silicon etching technique, to leave one or more "residual posts" of substrate material within cavity 1008.
  • silicon dioxide layer 804 may be wet-etched to retain corresponding residual posts.
  • the residual posts may serve to anchor and/or stiffen diaphragm 818.
  • a rapture threshold, rupture site, rupture pattern, and/or rupture time of diaphragm 818 may be defined, at least in part, by the residual posts.
  • cavity 1008 is formed in substrate 802 through a surface of substrate 802 that is opposite diaphragm 818.
  • cavity 1008 may be formed through another surface of substrate 802, such as a surface adj acent to diaphragm 818.
  • FIG. 11 is a flowchart of a method 1100 of disposing a diaphragm protector over a diaphragm, disposing a drug within a cavity, and sealing the cavity.
  • Method 1100 is described below with reference to example materials for illustrative purposes. Method 1100 is not, however, limited to the example materials described below.
  • FIG. 12 is a graphic illustration of a progression of stages of disposing a diaphragm protector over a diaphragm, disposing a drug within a cavity, and sealing the cavity. Method 1100 is not, however, limited to the examples of FIGS. 8, 10, and 12.
  • a layer 1202 of a diaphragm protector material such as polyethylene glycol (PEG), is spun onto diaphragm 818.
  • Layer 1202 may be spun to a thickness of greater than 10 um.
  • a shadow mask 1204 is disposed over exposed portions of substrate 802.
  • a drug 1210 is disposed within cavity 1008, such as by nebulization. Shadow mask 1204 is then removed. 1 027180
  • cavity 1008 is hermetically sealed with a substrate material 1212, such as described in one or more examples above.
  • substrate material 1212 may include an agent 1214, applied and/or affixed to an inner surface of substrate material 1212.
  • Agent 1214 may include a hydrogel, such as described in one or more examples above.
  • Cavity 1008 may be pressurized and/or evacuated, such as described in one or more examples herein.
  • substrate 802 including diaphragm 818, diaphragm protector layer 1202, drug 1210, substrate material 1212, and agent 1214, is mounted within a well of an implantable platform 1216, which may include a stent.
  • substrate 802 includes a plurality of drug-containing cavities 1008, the substrate may be cut into a plurality of substrates, each of which may include one or more cavities 1008, and which may mounted within a well of implantable platform 1216.
  • platform 1216 is implanted and diaphragm protector layer 1202 dissolves, degrades, and/or otherwise dissipates within the implant environment.
  • FIG. 13 is a block diagram of a drug delivery system 1300 to illustrate an example pattern formed within a surface of a rupturable diaphragm 1302.
  • FIG. 13 includes example dimensions. Methods and systems disclosed herein are not, however, limited to example dimensions disclosed herein.
  • FIG. 14 is a flowchart of a method 1400 of using an implantable pressure- actuated substance delivery system.
  • the substance delivery system may include:
  • an implant environment fluid is contacted to the substantially non-frangible layer within the implant environment.
  • the substantially non- frangible layer is dissipated within the implant environment in response to the contacting of the implant environment fluid.
  • the frangible layer of material is exposed to an implant environment pressure in response to the dissipating of the substantially non- frangible layer.
  • the frangible layer is ruptured.
  • the substance is released from the cavity into the implant environment through the substrate opening.
  • the substance delivery system may include a drug, such as described in one or more examples herein, which may include an anti-clotting agent.
  • a drug such as described in one or more examples herein, which may include an anti-clotting agent.
  • the substance delivery system may include one or more a sensory agent to invoke or elicit a sensory perception in patient, and a hydrogel, such as described in one or more examples herein. A method of using such a substance delivery system is described further below with reference to FIG. 16.
  • FIG. 15 is a flowchart of a method 1500 of using an implantable pressure- actuated drug delivery system within a vascular implant environment to treat a potential blood clot.
  • a drug delivery system is received within a vascular implant environment.
  • the vascular implant environment may include one or more of a cornary vascular implant environment and a non-coronary or peripherial vascular implant environment.
  • the drug delivery system may be received as an implantable platform, which may include a stent and/or a stand-lone drug delivery platform.
  • the drug delivery system may include include: a substrate;
  • thrombolytic drug or agent within a pressurized cavity of the substrate
  • a frangible layer of one or more materials disposed over a surface of the substrate, including over an opening to the cavity;
  • vascular implant environment fluid is contacted to the substantially non-frangible layer within the vascular implant environment.
  • the substantially non- frangible layer is dissipated within the vascular implant environment in response to the contacting of the vascular implant environment fluid.
  • the frangible layer of material is exposed to an vascular implant environment pressure (e.g., vascular blood pressure), in response to the dissipating of the substantially non-frangible layer.
  • an vascular implant environment pressure e.g., vascular blood pressure
  • the frangible layer is ruptured.
  • the thrombolytic agent is released from the cavity into the vascular implant environment through the substrate opening.
  • FIG. 16 is a flowchart of a method 1600 of using an implantable pressure- actuated substance delivery system that includes one or more of a hydrogel and a sensory agent.
  • Method 1600 includes features 1402 through 1414 of method 1400, and may include one or more of features 1602 through 1606.
  • an implant environment fluid is contact to a hydrogel within the substrate cavity.
  • the implant environment fluids of 1404 and 1604 may be the same fluid or different fluids within the implant environment.
  • the implant environment fluid of 1604 is absorbed by the hydrogel to expand the hydrogel within the cavity.
  • a sensory agent is released from the substrate cavity into the implant environment to invoke or elicit a sensory perception in the patient, such as described in one or more examples herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

La présente invention concerne des systèmes actionnés par pression implantables pour administrer un médicament et/ou une autre substance en réponse à une différence de pression entre une cavité du système et un environnement extérieur, et des procédés de fabrication et d'utilisation. Un diaphragme de membrane cassable par pression peut être ajusté pour se rompre à un seuil de rupture souhaité, un site de rupture souhaité, avec un motif de rupture souhaité, et/ou dans un délai de rupture souhaité. L'ajustement peut comprendre un choix de matériau, un contrôle de l'épaisseur, un modelage de surface, un modelage de support de substrat. La cavité peut être pressée au-dessus ou évacuée au-dessous du seuil de rupture, et une couche protectrice de diaphragme peut être disposée pour prévenir une rupture prématurée dans un environnement ambiant et se dissiper dans un environnement d'implant. Un système d'administration de médicament peut être mis en œuvre dans une endoprothèse pour libérer une substance après une diminution de pression artérielle. La cavité peut comprendre un médicament thrombolytique ou une autre substance pour traiter un caillot sanguin.
EP11707985.5A 2011-03-04 2011-03-04 Systèmes d'administration de médicament actionnés par pression implantables et procédés de fabrication et d'utilisation Withdrawn EP2680917A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/027180 WO2012121691A1 (fr) 2011-03-04 2011-03-04 Systèmes d'administration de médicament actionnés par pression implantables et procédés de fabrication et d'utilisation

Publications (1)

Publication Number Publication Date
EP2680917A1 true EP2680917A1 (fr) 2014-01-08

Family

ID=44625363

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11707985.5A Withdrawn EP2680917A1 (fr) 2011-03-04 2011-03-04 Systèmes d'administration de médicament actionnés par pression implantables et procédés de fabrication et d'utilisation

Country Status (4)

Country Link
EP (1) EP2680917A1 (fr)
JP (1) JP2014511246A (fr)
CA (1) CA2828954A1 (fr)
WO (1) WO2012121691A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903832C (fr) 2013-03-15 2022-03-22 Hyprotek, Inc. Dispositif d'injection a chambres multiples
US11304893B2 (en) 2017-07-24 2022-04-19 California Institute Of Technology Low power, chemically amplified, electrically removable barrier

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229901B1 (fr) * 1999-11-17 2009-03-18 Boston Scientific Limited Dispositifs microfabriques pour transport de molecules dans un fluide porteur
EP1341476A2 (fr) * 2000-12-01 2003-09-10 Nephros Therapeutics, Inc. Dispositif d'administration de medicaments intravasculaire et son utilisation
AU2003278881A1 (en) * 2002-09-23 2004-04-08 Microchips, Inc. Micro-reservoir osmotic release systems and microtube array device
US7476224B2 (en) * 2003-03-17 2009-01-13 Petrakis Dennis N Temperature responsive systems
WO2007042961A2 (fr) * 2005-10-11 2007-04-19 Koninklijke Philips Electronics N.V. Dispositif de liberation continue de molecules chimiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2012121691A1 *

Also Published As

Publication number Publication date
WO2012121691A1 (fr) 2012-09-13
CA2828954A1 (fr) 2012-09-13
JP2014511246A (ja) 2014-05-15

Similar Documents

Publication Publication Date Title
US10376682B2 (en) Method of manufacturing an implantable pressure-actuated drug delivery system
US11033378B2 (en) Medical device
JP2020114545A (ja) 医療用デバイス
US9180050B2 (en) Implantable intraocular pressure drain
EP1229901B1 (fr) Dispositifs microfabriques pour transport de molecules dans un fluide porteur
JP7122318B2 (ja) 緑内障治療のための統合房水シャント（ａｑｕｅｏｕｓ ｓｈｕｎｔ）
EP1173109B1 (fr) Extenseur multisection
US20120123388A1 (en) Method and apparatus for transport of substances into body tissue
US20100168644A1 (en) Glaucoma Treatment Device and Method
WO2004008504A1 (fr) Dispositifs a films minces tridimensionnels et procedes de fabrication
WO2000045744A1 (fr) Procede de protection de surface pour extenseurs et catheters a ballonnet d'administration medicamenteuse
EP2680917A1 (fr) Systèmes d'administration de médicament actionnés par pression implantables et procédés de fabrication et d'utilisation
US20220338889A1 (en) Methods and apparatus for plaque disruption
CN115721445A (zh) 一种用于急性脑卒中血管介入治疗的覆膜支架
JP2019136172A (ja) ステント

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140812

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141223